Page last updated: 2024-11-05

musk ambrette (artificial)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

musk ambrette (artificial): widely used fragrance implicated in contact photosensitivity; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6753
CHEMBL ID1373568
CHEBI ID82495
SCHEMBL ID155056
MeSH IDM0074146

Synonyms (84)

Synonym
STK725127
anisole, 6-tert-butyl-3-methyl-2,4-dinitro-
amber musk
2,6-dinitro-3-methoxy-4-tert-butyltoluene
musk ambrette, artificial
wln: wnr b1 do1 cnw ex1&1&1
synthetic musk ambrette
musk ambrette
6-tert-butyl-3-methyl-2,4-dinitroanisol
benzene,1-dimethylethyl)-2-methoxy-4-methyl-3,5-dinitro-
musk ambrette (artificial)
nsc-46122
nsc46122
nsc59845
nsc-59845
artificial musk ambrette
ai3-02439
musk ambrette (van)
nsc 46122
ambrette musk
2,6-dinitro-3-methoxy-1-methyl-4-tert-butylbenzene
4-tert-butyl-3-methoxy-1-methyl-2,6-dinitrobenzene
1-(1,1-dimethylethyl)-2-methoxy-4-methyl-3,5-dinitrobenzene
ccris 2390
4-methoxy-1,3-dinitro-2-methyl-5-tert-butylbenzene
brn 1889437
2,4-dinitro-3-methyl-6-tert-butylanisole
4-tert-butyl-3-methoxy-2,6-dinitrotoluene
anisole, 6-t-butyl-3-methyl-2,4-dinitro-
einecs 201-493-7
6-tert-butyl-3-methyl-2,4-dinitroanisole
OPREA1_084169
OPREA1_663268
inchi=1/c12h16n2o5/c1-7-9(13(15)16)6-8(12(2,3)4)11(19-5)10(7)14(17)18/h6h,1-5h
benzene,5-tert.butyl,1,3-dinitro,4-methoxy,2-methyl muscambrette
benzene, 1-(1,1-dimethylethyl)-2-methoxy-4-methyl-3,5-dinitro-
83-66-9
1-tert-butyl-2-methoxy-4-methyl-3,5-dinitrobenzene
NCGC00091130-01
NCIOPEN2_002280
B1379 ,
AKOS003093534
NCGC00091130-03
NCGC00091130-04
4-tert-butyl-2,6-dinitro-3-methoxytoluene
C19461
73507-41-2
benzene, 1-(1,1-dimethylethyl)-2-methoxy-4-methyl-, nitrated
musk ambrette paste
dtxcid705689
dtxsid7025689 ,
NCGC00258747-01
tox21_201195
cas-83-66-9
BBL011670
unii-55v150w8r6
hsdb 7693
4-06-00-03402 (beilstein handbook reference)
55v150w8r6 ,
FT-0619482
SCHEMBL155056
fema no. 2758 (gras delisted)
musk ambrette [iarc]
muskambrette
CHEBI:82495 ,
1-tert-butyl-2-methoxy-4-methyl-3,5-dinitro-benzene
1-(tert-butyl)-2-methoxy-4-methyl-3,5-dinitrobenzene
5-t-butyl-1,3-dinitro-4-methoxy-2-methylbenzene
1-tert-butyl-2-methoxy-4-methyl-3,5-dinitrobenzene #
2-tert-butyl-4,6-dinitro-5-methylanisole
1-methyl-4-t-butyl-3-methoxy-2,6-dinitrobenzene
SUAUILGSCPYJCS-UHFFFAOYSA-N
6-t-butyl-3-methyl-2,4-dinitroanisole
W-109302
CHEMBL1373568
mfcd00024268
AS-64958
musk ambrette 10 microg/ml in cyclohexane
4-t-butyl-3-methoxy-2,6-dinitrotoluene
1-(1,1-dimethylethyl)-2-methoxy-4-methylbenzene nitrated
Q26841326
AMY25109
E78966
CS-0314530

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Repeated daily dosing for 14 days resulted in little bioaccumulation for musk xylene and accumulation of about three-fold for musk ketone."( Dermal absorption and disposition of musk ambrette, musk ketone and musk xylene in rats.
Ford, RA; Hawkins, DR, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency56.23410.004023.8416100.0000AID485290
acetylcholinesteraseHomo sapiens (human)Potency31.47290.002541.796015,848.9004AID1347395; AID1347398
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency24.13870.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency18.03170.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoid X nuclear receptor alphaHomo sapiens (human)Potency20.48730.000817.505159.3239AID1159531
pregnane X nuclear receptorHomo sapiens (human)Potency9.60980.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency34.73260.000229.305416,493.5996AID588514; AID743075; AID743077
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency30.38880.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency23.87210.001628.015177.1139AID1224895; AID1259385; AID1259395
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency34.39420.057821.109761.2679AID1159526
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency31.62280.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency68.03200.000323.4451159.6830AID743065
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
Nuclear receptor ROR-gammaHomo sapiens (human)Potency0.33490.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (71)

TimeframeStudies, This Drug (%)All Drugs %
pre-199040 (56.34)18.7374
1990's18 (25.35)18.2507
2000's5 (7.04)29.6817
2010's7 (9.86)24.3611
2020's1 (1.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.21 (24.57)
Research Supply Index4.33 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.35%)5.53%
Reviews3 (4.05%)6.00%
Case Studies22 (29.73%)4.05%
Observational0 (0.00%)0.25%
Other48 (64.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]